Rezolute, Inc. (NASDAQ:RZLT) Stock Has Average Target Price of $11.22

Shares of Rezolute, Inc. (NASDAQ:RZLT) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $11.22.

Several research firms recently commented on RZLT. Zacks Research lowered shares of Rezolute from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. Cantor Fitzgerald raised shares of Rezolute from a “neutral” rating to an “overweight” rating in a research note on Monday, October 5th. HSBC upgraded shares of Rezolute to a “buy” rating in a report on Friday, September 25th. Citigroup reissued a “market outperform” rating on shares of Rezolute in a research report on Thursday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Thursday, October 15th.

Rezolute Stock Performance

RZLT opened at $3.96 on Monday. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46. The business has a 50 day moving average of $4.19 and a 200-day moving average of $3.90.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). As a group, analysts expect that Rezolute will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Rezolute

Several institutional investors and hedge funds have recently made changes to their positions in the company. AlphaCentric Advisors LLC boosted its stake in Rezolute by 4.5% during the 3rd quarter. AlphaCentric Advisors LLC now owns 75,495 shares of the company’s stock valued at $313,000 after purchasing an additional 3,240 shares during the last quarter. Auxano Advisors LLC purchased a new stake in shares of Rezolute during the second quarter valued at $52,000. Sequoia Financial Advisors LLC bought a new stake in Rezolute in the 2nd quarter worth about $75,000. WINTON GROUP Ltd bought a new stake in Rezolute in the 2nd quarter worth about $88,000. Finally, ADAR1 Capital Management LLC raised its position in Rezolute by 51.7% in the 1st quarter. ADAR1 Capital Management LLC now owns 58,679 shares of the company’s stock worth $179,000 after buying an additional 20,000 shares during the last quarter. Institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company’s lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.